【Molecular composition】：

【CAS】：755037-03-7

【source】：Regorafenib

【Certification】：

【Spec】：In-House

【DMF】：—

【use】：

Oncology API.

Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy